Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="MALAISE, M" or (type exact bookEditor and editor="MALAISE, M")

Add to list
Efficacy of bio-optimised curcuma extract (Flexofytol®) for painful knee osteoarthritis : data from COPRA, a multicenter randomised controlled study

Y Henrotin, M Malaise, Ruth Wittoek (UGent) , K Devlam, J-P Brasseur, F Luyten, Q Jiangang, Marthe Van Den Berghe (UGent) , R Uhoda, J Bentin, et al.

(2018) ANNALS OF THE RHEUMATIC DISEASES. 77(suppl. 2). p.790-790
Add to list
- Conference Paper
- C3
Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population

Bert Vander Cruyssen (UGent) , R WESTHOVENS, P DUREZ, Filip Van den Bosch (UGent) , Herman Mielants (UGent) , L DE CLERCK, A PERETZ, M MALAISE, L VERBRUGGEN, L DEWULF, et al.

(2008) SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 37. p.52-52
Add to list
- Journal Article
- A1
A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip

FP LUYTEN, P GEUSENS, M MALAISE, L DE CLERCK, R WESTHOVENS, F RAEMAN, D VANDER MIJNSBRUGGE, L MATHY, JP HAUZEUR, Filip De Keyser (UGent) , et al.

(2007) ANNALS OF THE RHEUMATIC DISEASES. 66(1). p.99-106
Add to list
- Conference Paper
- C3
Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition

Bert Vander Cruyssen (UGent) , R WESTHOVENS, P DUREZ, Filip Van den Bosch (UGent) , Herman Mielants (UGent) , L DE CLERCK, A PERETZ, M MALAISE, L VERBRUGGEN, N VASTESAEGER, et al.

(2006) ARTHRITIS AND RHEUMATISM. 54(9).
Add to list
- Journal Article
- A1
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Bert Vander Cruyssen (UGent) , Stijn Van Looy (UGent) , Bart Wyns (UGent) , R WESTHOVENS, P DUREZ, Filip Van den Bosch (UGent) , Herman Mielants (UGent) , L DE CLERCK, A PERETZ, M MALAISE, et al.

(2006) ARTHRITIS RESEARCH & THERAPY. 8(4).
Add to list
- Journal Article
- A1
Healthcare consumption and direct costs of rheumatoid arthritis in Belgium

R WESTHOVENS, A BOONEN, L VERBRUGGEN, P DUREZ, L DE CLERCK, M MALAISE and Herman Mielants (UGent)

(2005) CLINICAL RHEUMATOLOGY. 24(6). p.615-619
Add to list
- Journal Article
- A1
- open access
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

Bert Vander Cruyssen (UGent) , Stijn Van Looy (UGent) , Bart Wyns (UGent) , R WESTHOVENS, P DUREZ, M MALAISE, L VERBRUGGEN, N VASTESAEGER, A GELDHOF, Luc Boullart (UGent) , et al.

(2005) ARTHRITIS RESEARCH & THERAPY. 7(5).
Add to list
- Conference Paper
- C3
Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients

Bert Vander Cruyssen (UGent) , Stijn Van Looy (UGent) , R WESTHOVENS, P DUREZ, Filip Van den Bosch (UGent) , EM VEYS, L DE CLERCK, A PERETZ, M MALAISE, J DEVOGELAER, et al.

(2005) ANNALS OF THE RHEUMATIC DISEASES. 64. p.187-188
Add to list
- Conference Paper
- C3
DAS28 is a robust measure of the physician's clinical judgment of response infliximab therapy

Bert Vander Cruyssen (UGent) , Stijn Van Looy (UGent) , Bart Wyns (UGent) , R WESTHOVENS, P DUREZ, F VAN DEN BOSH, Eric Veys (UGent) , Herman Mielants (UGent) , Liselotte De Clerck (UGent) , A PERETZ, et al.

(2005) ARTHRITIS AND RHEUMATISM. 52(9).
Add to list
- Journal Article
- A1
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

N FRANCHIMONT, V PUTZEYS, J COLLETTE, S VERMEIRE, P RUTGEERTS, Martine De Vos (UGent) , A VAN GOSSUM, D FRANCHIMONT, R FIASSE, P PELCKMANS, et al.

(2004) ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 20(6). p.607-614
Add to list
- Journal Article
- A1
A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis

JR KIRWAN, R HALLGREN, Herman Mielants (UGent) , F WOLLHEIM, E BJORCK, T PERSSON, C BOOK, S BOWMAN, M BYRON, N COX, et al.

(2004) ANNALS OF THE RHEUMATIC DISEASES. 63(6). p.688-695
Add to list
- Journal Article
- A1
A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism.

E LOUIS, S VERMEIRE, P RUTGEERTS, Martine De Vos (UGent) , A VAN GOSSUM, P PESCATORE, R FIASSE, P PELCKMANS, H REYNAERT, G D'HAENS, et al.

(2002) SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 37(7). p.818-824
Add to list
- Journal Article
- A1
Production of interferon γ by peripheral blood mononuclear cells from normal subjects and from patients with rheumatoid arthritis

A Reuter, J Bernier, Y Vrindts Gevaert, R Meuleman Gathy, M Malaise, Walter Fiers and P Franchimont

(1988) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 6(4). p.347-354

Academic Bibliography

Efficacy of bio-optimised curcuma extract (Flexofytol®) for painful knee osteoarthritis : data from COPRA, a multicenter randomised controlled study

Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population

A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip

Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Healthcare consumption and direct costs of rheumatoid arthritis in Belgium

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients

DAS28 is a robust measure of the physician's clinical judgment of response infliximab therapy

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis

A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism.

Production of interferon γ by peripheral blood mononuclear cells from normal subjects and from patients with rheumatoid arthritis

Contents

Support

Contact